



Guidance for Interpreting CADEAS Referral to First Treatment Pathway Analysis

The Cancer Alliance Data, Evidence and Analysis Service (CADEAS) has carried out analysis of pathways with a Cancer Waiting Times (CWT) record for colorectal, lung and prostate cancers. The analysis builds on work previously carried out by RM Partners for the three Cancer Vanguard sites.

The aim of this work is to support the implementation of the best practice timed pathways; and to help Cancer Alliances further understand their CWT pathways in order to meet the 62-day CWT operational standard.

Graphs are presented for those on a 62-day pathway only.

How to interpret graphs

Example graph from the national report, showing variation in number of days from a CWT referral to first treatment received, by Cancer Alliance.


Figures on each bar show the median number of days from a CWT referral to first treatment for each geography. For the relevant geography each graph is presented as stacked column bar charts showing the proportion of patients with pathway length of 0-31 days; 32-52 days; 53-62 days and 100+ days. For example in England, just under 25% of patients had a referral to first treatment time of 0-31 days and just under 50% of patients had a referral of 0-52 days.

Cancer Alliances are grouped by region.

The numbers on each bar represent the median days taken from referral to treatment.

Each of the boxes represents the percentage of patients with a particular CWT referral to first treatment time interval in days. They represent categories shown in the legend. For example in England, just under 25% of patients had a referral to first treatment time of 0-31 days.

Colorectal cancer: variation in days from a referral to first treatment received, by Cancer Alliance (2017/18)



The x-axis variable and has 21 categories (19 Cancer Alliances, England as a benchmark and unknown). N = number of patients in each geography.

The legend shows the five categories of time intervals (in days) from CWT referral to first treatment.

Unknown group includes patients who were not able to be mapped to a Cancer Alliance due to missing CCG data in their CWT record.

Graph Title	Graph Description	Questions that can be asked
Variation in days from a CWT	These graphs show the variation in	Are the pathways longer for the
referral to first treatment	the amount of time taken from	Cancer Alliances/CCGs/trusts with the
<u>received</u>	referral to first treatment for	most patients?
(Colorectal cancer: slide 9)	colorectal, lung and prostate cancers	
(Lung cancer: slide 16)	for the Cancer Alliances in England	Is there an association between the
(Prostate cancer: slide 23)	or the CCGs/trusts in the Cancer	median days from referral to first
	Alliance. Identifying which Cancer	treatment and the proportion of
	Alliances/CCGs/trusts have the	patients meeting the operational
	shortest pathways (by median days	standard by cancer type and Cancer
	from referral to first treatment), and	Alliance/CCG/trust?
	the highest proportion of patients	
	that meet the operational standard,	What proportion of patients is waiting
	will enable best practice to be	100 days or more from referral to first
	shared and improvements to be	treatment?
	made in other Cancer	
	Alliances/CCGs/trusts.	For the CCGs/trusts with shorter
		pathways, is the Cancer Alliance
		aware of initiatives that have been
		implemented in this CCG/trust where
		best practice can be shared?
		Are the patterns the same for the
		different Cancer Alliances/CCGs/trusts
		for colorectal, lung and prostate
		cancers in England or the Cancer
		Alliance? And if not, why not?
Variation in first treatment	These graphs show the number of	Are the patterns in first treatment
modality received	patients receiving each treatment	modalities the same across the
(Colorectal cancer: slide 10)	modality as the first treatment for	different Cancer Alliances/CCGs/trusts
(Lung cancer: slide 17)	colorectal, lung and prostate cancers	for colorectal, lung and prostate
(Prostate cancer: slide 24)	for the Cancer Alliances/CCGs/trusts	cancers in England or the Cancer
(i restate carreer since 2 t)	in England or the Cancer Alliance.	Alliance? And if not, why not? For
	They provide information on	example, is surgery in colorectal
	resource use and show variation in	cancer associated with shorter
	first treatment received within and	pathways across all Cancer
	across Cancer Alliances/CCGs/trusts	Alliances/CCGs/trusts compared with
	in England or in a Cancer Alliance.	other treatment modalities in England
	in England of in a cancer / indirec.	or a particular Cancer Alliance?
Variation in days from a CWTs	These graphs show the variation in	Is there significant variation in
referral to first treatment	the amount of time taken from	pathway length between Cancer
received, by the three most	referral to first treatment for	Alliances/CCGs/trusts for the same
common treatment modalities	colorectal, lung and prostate cancers	tumour site and treatment modality?
(Colorectal cancer: slides 11-14)	for the three most common	If yes, why?
(Lung cancer: slides 18-21)	treatment modalities by Cancer	11 yC3, willy:
	7	Is there an association between the
(Prostate cancer: slides 25-28)	Alliance/CCG/trust.	
	Note: Forths All Course All's	median days from referral to first
	Note: For the All Cancer Alliance	treatment and the proportion of
	pack, time from referral to first	patients meeting the operational
	treatment is shown for the top five	standard by treatment modality,
	rather than the top 3 treatment	cancer type and Cancer

modalities in slides 11, 18and 25.	Alliance/CCG/trust?
modulities in sinces 11, 18ana 23.	Referral to first treatment pathway lengths varies by treatment modality e.g. in England for colorectal cancer, the median pathway length for surgery is shorter than that for chemotherapy. Is there an association between the referral to first treatment pathway lengths and treatment modality across different Cancer Alliances/CCGs/trusts?